Headquartered in Texas, MicroTransponder Inc. has developed the Paired Vagus Nerve Stimulation (Paired VNS™) Platform, based on decades of neuroscience research.

 

The Vivistim® System, for treatment of post-stroke upper limb impairment, is the first FDA-approved system on the platform. MicroTransponder is committed to expanding access to Vivistim for all stroke survivors, as well as pushing the limits of Paired VNS for other chronic neurologic conditions.